Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy
Thrombosis and Haemostasis · 01.05.2024 · 124 (05) · 387-398
DOI: 10.1055/a-2188-8898 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.05.2024. Verfasst von Caroline Dix und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Venous Thromboembolism, Transgender Persons. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Gender-affirming therapy involves the use of hormones to develop the physical characteristics of the identified gender and suppressing endogenous sex hormone production. Venous thromboembolism (VTE) is a known risk of exogenous estrogen therapy, and while evidence of VTE risk among transgender women using modern gender-affirming hormone therapy (GAHT) is still emerging, it is thought to affect up to 5% of transgender women. Historically, GAHT was associated with a high risk of VTE; however, modern preparations are less thrombogenic mainly due to significantly lower doses used as well as different preparations. This review presents the available literature regarding the following four topics: (1) risk of VTE among transgender women receiving estradiol GAHT, (2) how the route of administration of estradiol affects the VTE risk, (3) perioperative management of GAHT, (4) VTE risk among adolescents on GAHT. There is a need for large, longitudinal studies of transgender women using GAHT to further characterize VTE risk and how this is affected by factors such as patient age, duration of GAHT use, tobacco use, body mass index, and comorbidities. Future studies in these areas could inform the development of clinical guidelines to improve the care of transgender people.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia.
- Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Australia.
- Atherothrombosis and Vascular Biology Program, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
ORCID-Profile: Caroline Dix
Zitieren
APA
Dix, C., Moloney, M., Tran, H. A., & McFadyen, J. D. (2024). Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy. Thrombosis and Haemostasis, 124(05), 387-398. https://doi.org/10.1055/a-2188-8898
Vancouver
Dix C, Moloney M, Tran HA, McFadyen JD. Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy. Thrombosis and Haemostasis. 2024;124(05):387-398. doi:10.1055/a-2188-8898
BibTeX
@article{Dix2024,
author = {Dix, Caroline and Moloney, Mollie and Tran, Huyen A and McFadyen, James D},
title = {Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy},
journal = {Thrombosis and Haemostasis},
year = {2024},
volume = {124},
number = {05},
pages = {387--398},
doi = {10.1055/a-2188-8898}
}
EUVIMED